These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 29809231)

  • 41. Bihemispheric cerebral FDG PET correlates of cognitive dysfunction as assessed by the CERAD in Alzheimer's disease.
    Schönknecht OD; Hunt A; Toro P; Guenther T; Henze M; Haberkorn U; Schröder J
    Clin EEG Neurosci; 2011 Apr; 42(2):71-6. PubMed ID: 21675596
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The CERAD Neuropsychological Assessment Battery Is Sensitive to Alcohol-Related Cognitive Deficiencies in Elderly Patients: A Retrospective Matched Case-Control Study.
    Kaufmann L; Huber S; Mayer D; Moeller K; Marksteiner J
    J Int Neuropsychol Soc; 2018 Apr; 24(4):360-371. PubMed ID: 29103404
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Frontotemporal dementia, semantic dementia, and Alzheimer's disease: the contribution of standard neuropsychological tests to differential diagnosis.
    Diehl J; Monsch AU; Aebi C; Wagenpfeil S; Krapp S; Grimmer T; Seeley W; Förstl H; Kurz A
    J Geriatr Psychiatry Neurol; 2005 Mar; 18(1):39-44. PubMed ID: 15681627
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [CERAD and NOSGER. Comparing predictive scales for dementia in a Swiss gerontopsychiatric patient population].
    Künig G; Kaldune A; Stief V; Jäger M; Hell D; Endrass J; Schreiter Gasser U
    Nervenarzt; 2007 Mar; 78(3):314, 316-21. PubMed ID: 16404633
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The CERAD Neuropsychological Battery in Patients with Idiopathic Normal Pressure Hydrocephalus Compared with Normal Population and Patients with Mild Alzheimer's Disease.
    Nerg O; Junkkari A; Hallikainen I; Rauramaa T; Luikku A; Hiltunen M; Jääskeläinen JE; Leinonen V; Hänninen T; Koivisto A
    J Alzheimers Dis; 2021; 81(3):1117-1130. PubMed ID: 33896842
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nicotinic α4β2 acetylcholine receptors and cognitive function in Parkinson's disease.
    Lorenz R; Samnick S; Dillmann U; Schiller M; Ong MF; Faßbender K; Buck A; Spiegel J
    Acta Neurol Scand; 2014 Sep; 130(3):164-71. PubMed ID: 24762290
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of the Korean version of the Consortium to Establish a Registry for Alzheimer's Disease Assessment Packet (CERAD-K): clinical and neuropsychological assessment batteries.
    Lee JH; Lee KU; Lee DY; Kim KW; Jhoo JH; Kim JH; Lee KH; Kim SY; Han SH; Woo JI
    J Gerontol B Psychol Sci Soc Sci; 2002 Jan; 57(1):P47-53. PubMed ID: 11773223
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Accuracy of a Brief Neuropsychological Battery for the Diagnosis of Dementia and Mild Cognitive Impairment: An Analysis of the NEDICES Cohort.
    Serna A; Contador I; Bermejo-Pareja F; Mitchell AJ; Fernández-Calvo B; Ramos F; Villarejo A; Benito-León J
    J Alzheimers Dis; 2015; 48(1):163-73. PubMed ID: 26401937
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The relationship between extrapyramidal signs and cognitive performance in patients with Alzheimer's disease enrolled in the CERAD Study. Consortium to Establish a Registry for Alzheimer's Disease.
    Clark CM; Ewbank D; Lerner A; Doody R; Henderson VW; Panisset M; Morris JC; Fillenbaum GG; Heyman A
    Neurology; 1997 Jul; 49(1):70-5. PubMed ID: 9222172
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analyzing the subcortical dementia syndrome of Parkinson's disease using the RBANS.
    Beatty WW; Ryder KA; Gontkovsky ST; Scott JG; McSwan KL; Bharucha KJ
    Arch Clin Neuropsychol; 2003 Jul; 18(5):509-20. PubMed ID: 14591446
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Visuo-constructional functions in patients with mild cognitive impairment, Alzheimer's disease, and Parkinson's disease.
    Lehrner J; Krakhofer H; Lamm C; Macher S; Moser D; Klug S; Dal-Bianco P; Pirker W; Auff E; Pusswald G
    Neuropsychiatr; 2015; 29(3):112-9. PubMed ID: 25861769
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Considering the base rates of low performance in cognitively healthy older adults improves the accuracy to identify neurocognitive impairment with the Consortium to Establish a Registry for Alzheimer's Disease-Neuropsychological Assessment Battery (CERAD-NAB).
    Mistridis P; Egli SC; Iverson GL; Berres M; Willmes K; Welsh-Bohmer KA; Monsch AU
    Eur Arch Psychiatry Clin Neurosci; 2015 Aug; 265(5):407-17. PubMed ID: 25555899
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Practical application of the CERAD test battery as a neuropsychological dementia screening test].
    Satzger W; Hampel H; Padberg F; Bürger K; Nolde T; Ingrassia G; Engel RR
    Nervenarzt; 2001 Mar; 72(3):196-203. PubMed ID: 11268764
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [CERAD-NP battery: Age-, gender- and education-specific reference values for selected subtests. Results of the German Study on Ageing, Cognition and Dementia in Primary Care Patients (AgeCoDe)].
    Luck T; Riedel-Heller SG; Wiese B; Stein J; Weyerer S; Werle J; Kaduszkiewicz H; Wagner M; Mösch E; Zimmermann T; Maier W; Bickel H; van den Bussche H; Jessen F; Fuchs A; Pentzek M;
    Z Gerontol Geriatr; 2009 Oct; 42(5):372-84. PubMed ID: 19639242
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of the Montreal Cognitive Assessment and Alzheimer's Disease-8 as cognitive screening measures in Parkinson's disease.
    Brown DS; Bernstein IH; McClintock SM; Munro Cullum C; Dewey RB; Husain M; Lacritz LH
    Int J Geriatr Psychiatry; 2016 Mar; 31(3):264-72. PubMed ID: 26177715
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Object alternation and orbitofrontal system dysfunction in Alzheimer's and Parkinson's disease.
    Freedman M
    Brain Cogn; 1990 Nov; 14(2):134-43. PubMed ID: 2285509
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cognitive decline in the behavioral variant of frontotemporal dementia.
    Diehl-Schmid J; Bornschein S; Pohl C; Förstl H; Kurz A; Jahn T
    Int Psychogeriatr; 2011 Mar; 23(2):230-7. PubMed ID: 20836915
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diagnosis of possible mild cognitive impairment in Parkinson's disease: validity of the SCOPA-Cog.
    Isella V; Mapelli C; Morielli N; Siri C; De Gaspari D; Pezzoli G; Antonini A; Poletti M; Bonuccelli U; Picchi L; Napolitano A; Vista M; Appollonio IM
    Parkinsonism Relat Disord; 2013 Dec; 19(12):1160-3. PubMed ID: 24011719
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Age-, sex-, and education-specific norms for an extended CERAD Neuropsychological Assessment Battery-Results from the population-based LIFE-Adult-Study.
    Luck T; Pabst A; Rodriguez FS; Schroeter ML; Witte V; Hinz A; Mehnert A; Engel C; Loeffler M; Thiery J; Villringer A; Riedel-Heller SG
    Neuropsychology; 2018 May; 32(4):461-475. PubMed ID: 29517259
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Screening Mild and Major Neurocognitive Disorders in Parkinson's Disease.
    Lucza T; Karádi K; Kállai J; Weintraut R; Janszky J; Makkos A; Komoly S; Kovács N
    Behav Neurol; 2015; 2015():983606. PubMed ID: 26078489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.